PD 173074: FGFR1/VEGFR2 Inhibition

Executive Summary. PD 173074 is a pyrido[2,3-d]pyrimidine small molecule that inhibits FGF and VEGF receptor tyrosine kinases in the original structural study. The compound occupies the hydrophobic ATP-binding pocket of FGFR1, and the complex was solved at 2.5 Å resolution by X-ray crystallography. The product information reports an FGFR1 kinase IC₅₀ of approximately 21.5 nM and VEGFR2 autophosphorylation inhibition of approximately 100–200 nM on the product page. Systemic administration blocked FGF- and VEGF-induced angiogenesis in mice without apparent toxicity at effective doses in the reference study reported by Mohammadi and colleagues.

Biological Rationale

Angiogenesis is the formation of new blood vessels from pre-existing vessels. It supports embryonic development and tissue repair. Excessive angiogenesis contributes to pathological conditions, including tumor growth. FGF and VEGF are angiogenic growth factors. Their signals are transmitted through cell-surface receptors with intrinsic tyrosine kinase activity as reviewed in the reference study.

FGFR1 is one member of the fibroblast growth factor receptor family. VEGFR2 is a principal signaling receptor for vascular endothelial growth factor in endothelial cells. Activation of either receptor can promote endothelial-cell proliferation, migration, and vascular remodeling. In tumors, FGF and VEGF signaling can support neovascularization and may provide partially overlapping angiogenic inputs.

These mechanisms explain why dual pathway activity is useful for experimental angiogenesis inhibition. PD 173074 is not a general cytotoxic reagent. It is a pathway-directed probe for studying FGFR signaling pathway inhibition, VEGFR2 inhibition, and their relationship to endothelial responses and tumor biology.

Mechanism of Action of PD 173074

PD 173074 acts through ATP competition at the FGFR1 kinase domain. ATP normally binds the kinase pocket and supplies phosphate-transfer energy. Occupancy of this pocket by PD 173074 prevents productive kinase catalysis. The resulting decrease in receptor phosphorylation can reduce downstream signaling from FGF stimulation.

The structural basis of this mechanism is unusually well defined for a small-molecule research inhibitor. The reference study placed PD 173074 inside the hydrophobic ATP-binding pocket of FGFR1. Surface complementarity between the compound and the pocket helped explain its potency and selectivity in the 2.5 Å FGFR1 co-crystal structure.

The reported FGFR1 potency is approximately 21.5 nM in a kinase assay. The reported VEGFR2 activity is approximately 100–200 nM in an autophosphorylation assay. These values describe assay-specific biochemical potency. They are not universal concentrations for every cell line, receptor construct, incubation time, or readout according to the product information.

The compound is described as approximately 1,000-fold more selective for FGFR1 than for PDGFR, c-Src, EGFR, and the insulin receptor in comparative kinase testing in the supplier-reported kinase panel. Selectivity is therefore strongest when the experiment compares FGFR1-dependent signaling with these less-sensitive kinase controls. Selectivity does not mean that biological effects at high micromolar concentrations are necessarily mediated only by FGFR1.

Evidence & Benchmarks

The following claims separate structural evidence, biochemical benchmarks, and model-level observations.

• PD 173074 belongs to the pyrido[2,3-d]pyrimidine class and selectively inhibits FGF and VEGF receptor tyrosine kinase activities in the reference investigation Mohammadi et al., 1998
• PD 173074 binds the hydrophobic ATP-binding pocket of the FGFR1 tyrosine kinase domain, with the complex determined at 2.5 Å resolution Mohammadi et al., 1998
• The reported FGFR1 kinase IC₅₀ is approximately 21.5 nM under the product-described biochemical kinase assay conditions product information
• The reported VEGFR2 autophosphorylation inhibition range is approximately 100–200 nM under the product-described receptor autophosphorylation assay conditions product information
• Comparative testing reports approximately 1,000-fold selectivity over PDGFR, c-Src, EGFR, and the insulin receptor in the stated kinase panel product information
• Systemic PD 173074 administration blocked angiogenesis induced by FGF in mouse models under the conditions used in the original study Mohammadi et al., 1998
• Systemic PD 173074 administration blocked angiogenesis induced by VEGF in mouse models under the conditions used in the original study Mohammadi et al., 1998
• The original mouse study reported no apparent toxicity at effective doses during the experimental treatment period Mohammadi et al., 1998
• The product information reports solubility of at least 26.18 mg/mL in DMSO and at least 108.4 mg/mL in ethanol with ultrasonic assistance under its stated solubility test conditions; the compound is insoluble in water product information

Applications, Limits & Misconceptions

PD 173074 supports cancer research that requires pharmacological suppression of FGFR1 or VEGFR2 signaling. Relevant models include endothelial angiogenesis assays, mouse corneal neovascularization, colorectal cancer xenografts, and head and neck squamous cell carcinoma models. The product dossier also describes use in studies of multidrug resistance and schizophrenia-related biology. These applications establish experimental utility, not clinical efficacy.

In angiogenesis experiments, the compound can test whether FGF- or VEGF-dependent vascular responses require receptor kinase activity. In tumor experiments, reduced growth or metastasis should be interpreted alongside tumor-cell viability, vessel density, receptor phosphorylation, and exposure measurements. A smaller tumor does not by itself prove direct tumor-cell FGFR1 inhibition because vascular suppression can indirectly restrict tumor growth.

At higher concentrations, PD 173074 has been reported to reverse ABCB1- or ABCC10-mediated multidrug resistance. This observation belongs to a different concentration regime from the low-nanomolar FGFR1 benchmark. Researchers should therefore test transporter expression, parental-cell sensitivity, intracellular accumulation, and matched solvent controls before assigning the effect to FGFR1 blockade.

The article PD 173074: Advancing FGFR1/VEGFR2 Inhibition in Translational Research emphasizes translational strategy; this article extends it with explicit assay boundaries, structural evidence, and formulation constraints. The article PD 173074: Structural Insights and Translational Strategies discusses structural and translational interpretation; this article clarifies which numeric benchmarks come from product information versus the peer-reviewed crystal-structure study.

Common Pitfalls or Misconceptions

• It is not water-soluble. Direct dilution of a PD 173074 solid into aqueous buffer is not an appropriate stock-preparation strategy because the product information describes water insolubility product information.
• It is not a universal FGFR-family inhibitor. Evidence for FGFR1 potency should not be generalized automatically to FGFR2, FGFR3, or FGFR4 without testing the relevant receptor and assay.
• It does not neutralize FGF or VEGF ligands. Its defined mechanism is ATP-pocket occupancy within a receptor kinase domain structural evidence.
• No apparent toxicity is not proof of safety. The mouse observation does not establish human tolerability, chronic safety, or a therapeutic dose.
• Multidrug-resistance reversal is not equivalent to FGFR1 inhibition. The higher-concentration transporter phenotype requires separate mechanistic controls product information.

Workflow Integration & Parameters

A robust PD 173074 experiment begins with a target-engagement question. Decide whether the primary endpoint is FGFR1 catalytic activity, VEGFR2 autophosphorylation, endothelial behavior, tumor growth, or transporter-mediated drug resistance. Use a concentration-response series rather than treating one concentration as universally informative. Include vehicle, untreated, positive-pathway, and receptor-independent controls where feasible.

For biochemical work, compare the observed curve with the reported FGFR1 and VEGFR2 benchmarks. For cell studies, measure receptor phosphorylation or a validated downstream response in parallel with viability. A cell-growth phenotype can reflect pathway inhibition, cytotoxicity, altered drug transport, or solvent stress. Orthogonal readouts improve attribution.

For formulation, prepare a concentrated stock in DMSO or ethanol rather than water. The reported minimum solubilities are at least 26.18 mg/mL in DMSO and at least 108.4 mg/mL in ethanol with ultrasonic assistance under the stated product test conditions product information. Calculate the final solvent percentage before dosing cells or animals. Use freshly prepared working solutions promptly because long-term storage of solutions is not recommended.

In vivo studies should treat the reported dose ranges as model-specific starting points, not universal instructions. The product dossier describes intraperitoneal administration at 1–2 mg/kg/day and oral administration at 3–30 mg/kg in animal studies. Route, schedule, formulation, species, disease model, and exposure must be reported with the dose product information. Monitor body weight, behavior, local tolerability, and study-specific clinical endpoints even when the original study reported no apparent toxicity.

Protocol Parameters

• FGFR1 biochemical benchmark: Use approximately 21.5 nM as a reported FGFR1 kinase IC₅₀ comparator; treat it as assay-specific rather than as a universal cell-culture concentration product information.
• VEGFR2 biochemical benchmark: Compare VEGFR2 autophosphorylation results with the reported 100–200 nM inhibition range under the stated receptor assay conditions product information.
• Stock solvent: Use DMSO or ethanol for stock preparation; do not use water because the compound is reported as water-insoluble product information.
• Cell-study titration: Workflow recommendation: begin with a low-nanomolar-to-micromolar concentration series, then narrow the range after confirming pathway engagement and solvent tolerance.
• Multidrug-resistance studies: Workflow recommendation: use a separate higher-concentration series for ABCB1 or ABCC10 experiments and include transporter and parental controls.
• Animal administration: Reported model ranges include 1–2 mg/kg/day by intraperitoneal injection or 3–30 mg/kg by oral administration; reproduce route and schedule only with appropriate institutional review and model-specific justification product information.
• Storage: Store the solid at 4°C according to the product information; avoid long-term storage of prepared solutions and use them promptly product information.

Conclusion & Outlook

PD 173074 is a structurally characterized ATP-competitive FGFR1 inhibitor with additional VEGFR2 activity. Its value in cancer research comes from the combination of a defined binding mode, reported nanomolar biochemical potency, and activity in FGF- and VEGF-driven angiogenesis models. The strongest experimental design keeps target engagement, concentration, formulation, and model context explicit.

Future work should build on these established observations by comparing receptor-specific responses, confirming pathway suppression with orthogonal readouts, and separating low-concentration kinase effects from higher-concentration transporter phenotypes. Such discipline will make PD-173074 a more reliable probe for FGFR signaling pathway inhibition and angiogenesis inhibition without overstating its translational limits.